Mathieu Le Gars

6.0k total citations
21 papers, 316 citations indexed

About

Mathieu Le Gars is a scholar working on Infectious Diseases, Epidemiology and Immunology. According to data from OpenAlex, Mathieu Le Gars has authored 21 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 7 papers in Epidemiology and 5 papers in Immunology. Recurrent topics in Mathieu Le Gars's work include SARS-CoV-2 and COVID-19 Research (11 papers), COVID-19 Clinical Research Studies (6 papers) and Influenza Virus Research Studies (5 papers). Mathieu Le Gars is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (11 papers), COVID-19 Clinical Research Studies (6 papers) and Influenza Virus Research Studies (5 papers). Mathieu Le Gars collaborates with scholars based in United States, Netherlands and Belgium. Mathieu Le Gars's co-authors include Jean‐Michel Sallenave, Michel Chignard, Delphyne Descamps, Catherine A. Blish, Bénédicte Manoury, Diane Barbier, Mira Tohmé, Reuben Ramphal, Sophia Maschalidi and Viviane Balloy and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Immunology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Mathieu Le Gars

19 papers receiving 312 citations

Peers

Countries citing papers authored by Mathieu Le Gars

Since Specialization

Citations

This map shows the geographic impact of Mathieu Le Gars's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathieu Le Gars with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathieu Le Gars more than expected).

Fields of papers citing papers by Mathieu Le Gars

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathieu Le Gars. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathieu Le Gars. The network helps show where Mathieu Le Gars may publish in the future.

Co-authorship network of co-authors of Mathieu Le Gars

This figure shows the co-authorship network connecting the top 25 collaborators of Mathieu Le Gars. A scholar is included among the top collaborators of Mathieu Le Gars based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathieu Le Gars. Mathieu Le Gars is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial 2025 ·EClinicalMedicine ·(unknown), (unknown), Nathalie Vaissière, Carla Truyers, (unknown), Erik Buntinx, Mathieu Le Gars, Frank Struyf, Gert C. Scheper, Macaya Douoguih, Javier Ruiz‐Guiñazú, (unknown), Wenhua Ling, (unknown), M. de Groot, Maria Grazia Pau, (unknown), Sunila Pradeep, (unknown), (unknown)	1
2	The epigenomic landscape of bronchial epithelial cells reveals the establishment of trained immunity 2025 ·Genes and Immunity ·Jeanne Bigot, Rachel Legendre, (unknown), Sébastien Jacques, Mathieu Le Gars, (unknown), Loïc Guillot, Harriet Corvol, Christophe Hennequin, J. Guitard, Jean‐Yves Coppée, Viviane Balloy, Claudia Chica	0
3	Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial 2025 ·EBioMedicine ·Nina Hertoghs, (unknown), (unknown), Jerald Sadoff, Barbara L. Banbury, Nicholas K. Akers, Bryan Howie, Harlan Robins, (unknown), Jeroen Tolboom, Veronica V. Rezelj, Jenny Hendriks, Hanneke Schuitemaker, Daniel J Stieh, Mathieu Le Gars	1
4	Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy 2025 ·Human Vaccines & Immunotherapeutics ·(unknown), (unknown), Cynthia Robinson, Benoît Baron, D. Lowson, (unknown), Veronica V. Rezelj, Anne Marit de Groot, (unknown), (unknown), Mathieu Le Gars, Frank Struyf, Javier Ruiz‐Guiñazú	1
5	Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial 2024 ·Vaccine ·Mathieu Le Gars, Jerald Sadoff, Vicky Cárdenas, Dirk Heerwegh, (unknown), (unknown), C. C. Spicer, (unknown), (unknown), (unknown), Frank Struyf, Hanneke Schuitemaker, Macaya Douoguih	0
6	Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study 2024 ·Vaccine ·Vicky Cárdenas, Mathieu Le Gars, Carla Truyers, Javier Ruiz‐Guiñazú, Frank Struyf, (unknown), Marc J. M. Bonten, Alberto M. Borobia, Emil C. Reisinger, Ingrid M. C. Kamerling, Macaya Douoguih, Jerald Sadoff	2
7	B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S 2024 ·iScience ·Catherine Jacob-Dolan, Michelle A. Lifton, Olivia Powers, Jessica Miller, Nicole P. Hachmann, (unknown), Nehalee Surve, Camille R. Mazurek, (unknown), (unknown), Robert C. Patio, (unknown), Mathieu Le Gars, Jerald Sadoff, Aaron G. Schmidt, Dan H. Barouch	2
8	Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Philippe Jacqmin, Yuki Iwaki, (unknown), Mathieu Le Gars, Jerald Sadoff, Karin Hardt, Javier Ruiz‐Guiñazú, Juan José Pérez Ruixo	4
9	Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan 2023 ·Vaccine ·(unknown), Hiroshi Tamura, Koji Fujii, (unknown), Kiichiro Toyoizumi, Tina Liu, Mathieu Le Gars, Vicky Cárdenas, Takashi Eto	4
10	Quantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach 2022 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), Mathieu Le Gars, Belén Valenzuela, Georgi Shukarev, Vicky Cárdenas, Javier Ruiz‐Guiñazú, Jerald Sadoff, Richard M. W. Hoetelmans, Juan José Pérez Ruixo	5
11	Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials 2022 ·Vaccine ·Jerald Sadoff, Mathieu Le Gars, Boerries Brandenburg, Vicky Cárdenas, Georgi Shukarev, Nathalie Vaissière, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Mandy Jongeneelen, Krisztián Kaszás, Jeroen Tolboom, Gert C. Scheper, Jenny Hendriks, Javier Ruiz‐Guiñazú, Frank Struyf, Johan Van Hoof, Macaya Douoguih, Hanneke Schuitemaker	14
12	Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age 2022 ·Human Vaccines & Immunotherapeutics ·Anna Lisa Ong‐Lim, Georgi Shukarev, (unknown), (unknown), (unknown), (unknown), Gert C. Scheper, (unknown), Mathieu Le Gars, (unknown), Hanneke Schuitemaker, Macaya Douoguih, Jeanne‐Marie Jacquet	2
13	Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine 2022 ·Immunological Reviews ·Mathieu Le Gars, Jenny Hendriks, Jerald Sadoff, Martin Ryser, Frank Struyf, Macaya Douoguih, Hanneke Schuitemaker	14
14	CytoGLMM: conditional differential analysis for flow and mass cytometry experiments 2021 ·BMC Bioinformatics ·Christof Seiler, Anne-Maud Ferreira, (unknown), Laura J. Simpson, Mathieu Le Gars, Elena Vendrame, Catherine A. Blish, Susan Holmes	17
15	Pregnancy-Induced Alterations in NK Cell Phenotype and Function 2019 ·Frontiers in Immunology ·Mathieu Le Gars, Christof Seiler, Alexander Kay, Nicholas Bayless, Elina Starosvetsky, Lindsay S. Moore, Shai S. Shen-Orr, Natali Aziz, Purvesh Khatri, Cornelia L. Dekker, Gary E. Swan, Mark M. Davis, Susan Holmes, Catherine A. Blish	34
16	Quand les cellules iNKT partent au charbon : nouvelles pistes thérapeutiques 2017 ·médecine/sciences ·Mathieu Le Gars, (unknown), (unknown), Christophe Paget, François Trottein, Pierre L. Goossens, Jean‐Nicolas Tournier	1
17	Increased Proinflammatory Responses of Monocytes and Plasmacytoid Dendritic Cells to Influenza A Virus Infection During Pregnancy 2016 ·The Journal of Infectious Diseases ·Mathieu Le Gars, Alexander Kay, Nicholas Bayless, Natali Aziz, Cornelia L. Dekker, Gary E. Swan, Mark M. Davis, Catherine A. Blish	38
18	Mechanisms of Invariant NKT Cell Activity in Restraining Bacillus anthracis Systemic Dissemination 2016 ·The Journal of Immunology ·Mathieu Le Gars, (unknown), (unknown), Christophe Paget, François Trottein, Pierre L. Goossens, Jean‐Nicolas Tournier	4
19	Neutrophil Elastase Degrades Cystic Fibrosis Transmembrane Conductance Regulator via Calpains and Disables Channel Function In Vitro and In Vivo 2012 ·American Journal of Respiratory and Critical Care Medicine ·Mathieu Le Gars, Delphyne Descamps, Delphine Roussel, Emilie Saussereau, Loïc Guillot, Manon Ruffin, Olivier Tabary, Saw-See Hong, Pierre Boulanger, Marc Paulais, Laurette Malleret, Azzaq Belaaouaj, Aleksander Edelman, Michel Huerre, Michel Chignard, Jean‐Michel Sallenave	84
20	Toll-like receptor 5 (TLR5), IL-1β secretion, and asparagine endopeptidase are critical factors for alveolar macrophage phagocytosis and bacterial killing 2012 ·Proceedings of the National Academy of Sciences ·Delphyne Descamps, Mathieu Le Gars, Viviane Balloy, Diane Barbier, Sophia Maschalidi, Mira Tohmé, Michel Chignard, Reuben Ramphal, Bénédicte Manoury, Jean‐Michel Sallenave	81

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact